Propellon Therapeutics

Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, which is crucial for the assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and the dysregulation of epigenetic mechanisms are associated with various cancers and linked to poor patient survival. Propellon's WDR5 inhibitor platform, established by FACIT, originated from discoveries, research, and innovation at OICR.